Gilead Sciences Inc (GILD)vsMolson Coors Brewing Co Class B (TAP)
GILD
Gilead Sciences Inc
$131.33
-2.04%
HEALTHCARE · Cap: $166.40B
TAP
Molson Coors Brewing Co Class B
$42.41
-1.67%
CONSUMER DEFENSIVE · Cap: $8.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Gilead Sciences Inc generates 163% more annual revenue ($29.44B vs $11.19B). GILD leads profitability with a 28.9% profit margin vs -18.9%. GILD appears more attractively valued with a PEG of 0.38. GILD earns a higher WallStSmart Score of 72/100 (B).
GILD
Strong Buy72
out of 100
Grade: B
TAP
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+43.2%
Fair Value
$236.08
Current Price
$131.33
$104.75 discount
Margin of Safety
+59.8%
Fair Value
$132.44
Current Price
$42.41
$90.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 37.4%
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Earnings expanding 23.4% YoY
Reasonable price relative to book value
Earnings expanding 35.6% YoY
Areas to Watch
4.7% revenue growth
2.0% revenue growth
Expensive relative to growth rate
ROE of -18.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : GILD
The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bull Case : TAP
The strongest argument for TAP centers on Price/Book, EPS Growth.
Bear Case : GILD
The primary concerns for GILD are Revenue Growth.
Bear Case : TAP
The primary concerns for TAP are Revenue Growth, PEG Ratio, Return on Equity.
Key Dynamics to Monitor
GILD profiles as a value stock while TAP is a turnaround play — different risk/reward profiles.
TAP carries more volatility with a beta of 0.44 — expect wider price swings.
GILD is growing revenue faster at 4.7% — sustainability is the question.
GILD generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
GILD scores higher overall (72/100 vs 56/100), backed by strong 28.9% margins. TAP offers better value entry with a 59.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gilead Sciences Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Molson Coors Brewing Co Class B
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
The Molson Coors Beverage Company, commonly known as Molson Coors, is a multinational drink and brewing company headquartered in Chicago in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?